Literature DB >> 28146465

Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.

Anna Tomaszuk-Kazberuk, Paulina Łopatowska, Elżbieta Młodawska, Joanne van Ryn, Paul A Reilly, Charles V Pollack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28146465     DOI： 10.20452/pamw.3918

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN： 0032-3772


× No keyword cloud information.
  3 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

Review 2.  Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?

Authors:  Elzbieta Mlodawska; Paulina Lopatowska; Jolanta Malyszko; Maciej Banach; Bożena Sobkowicz; Adrian Covic; Anna Tomaszuk-Kazberuk
Journal:  Int Urol Nephrol       Date:  2018-05-21       Impact factor: 2.370

3.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.